TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas and currently employs 19 full-time employees. The company went IPO on 2019-10-25. The company is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

Industry: Pharmaceutical Preparations Peers: SEELOS THERAPEUTICS, INC. Assertio Holdings Inc LeonaBio Inc CorMedix Inc DURECT CORP ImageneBio Inc Johnson & Johnson Paratek Pharmaceuticals, Inc. Trevi Therapeutics Inc Verrica Pharmaceuticals Inc